This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
- Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
- Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
- Bispecific Antibody Pretargeting of Radionuclides for Immuno-Single-Photon Emission Computed Tomography and Immuno-Positron Emission Tomography Molecular Imaging: An Update
- A Phase I Trial Combining High-Dose 90Y-Labeled Humanized Anti-CEA Monoclonal Antibody with Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- 18F-FDG PET Detection of Lymph Node Metastases in Medullary Thyroid Carcinoma
- Successful Surgical Removal of Occult Metastases of Medullary Thyroid Carcinoma Recurrences with the Help of Immunoscintigraphy and Radioimmunoguided Surgery